VALNEVA news, videos and press releases
For more news please use our advanced search feature.
VALNEVA - More news...
VALNEVA - More news...
- Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
- Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
- Declaration of voting rights - Valneva SE, March 2024
- Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
- Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
- Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
- Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
- Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
- VALNEVA: Declaration of shares and voting rights - January 31, 2024
- Valneva Announces Sale of Priority Review Voucher for $103 Million
- Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
- Valneva Provides Updated 2023 Financial Guidance
- Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors
- Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15
- EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment
- VALNEVA Declaration of shares and voting rights: October 31, 2023
- Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment
- VALNEVA - Declaration of shares and voting rights: September 30, 2023
- Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million
- Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
- Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
- Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate
- Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate
- VALNEVA Declaration of shares and voting rights - July 31, 2023
- Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet
- Valneva Files for Chikungunya Vaccine Authorization with Health Canada
- VALNEVA - Declaration of shares and voting rights - April 30, 2023
- VALNEVA - Declaration of shares and voting rights - March 31, 2023
- Valneva Announces Filing of 2022 Universal Registration Document and US Form 20-F
- Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001